173 related articles for article (PubMed ID: 24700876)
61. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.
Dousa TP
Kidney Int; 1999 Jan; 55(1):29-62. PubMed ID: 9893113
[TBL] [Abstract][Full Text] [Related]
62. Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes.
Jurevicius J; Skeberdis VA; Fischmeister R
J Physiol; 2003 Aug; 551(Pt 1):239-52. PubMed ID: 12815180
[TBL] [Abstract][Full Text] [Related]
63. Nephrocystin-3 is required for ciliary function in zebrafish embryos.
Zhou W; Dai J; Attanasio M; Hildebrandt F
Am J Physiol Renal Physiol; 2010 Jul; 299(1):F55-62. PubMed ID: 20462968
[TBL] [Abstract][Full Text] [Related]
64. Zebrafish Model as a Screen to Prevent Cyst Inflation in Autosomal Dominant Polycystic Kidney Disease.
Oliveira I; Jacinto R; Pestana S; Nolasco F; Calado J; Lopes SS; Roxo-Rosa M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445719
[TBL] [Abstract][Full Text] [Related]
65. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis.
Abusnina A; Alhosin M; Keravis T; Muller CD; Fuhrmann G; Bronner C; Lugnier C
Cell Signal; 2011 Jan; 23(1):152-60. PubMed ID: 20807569
[TBL] [Abstract][Full Text] [Related]
66. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
67. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
68. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.
Zhu P; Sieben CJ; Xu X; Harris PC; Lin X
Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903
[TBL] [Abstract][Full Text] [Related]
69. Therapeutic advances in the treatment of polycystic kidney disease.
Riella C; Czarnecki PG; Steinman TI
Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
[TBL] [Abstract][Full Text] [Related]
70. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation.
Magenheimer BS; St John PL; Isom KS; Abrahamson DR; De Lisle RC; Wallace DP; Maser RL; Grantham JJ; Calvet JP
J Am Soc Nephrol; 2006 Dec; 17(12):3424-37. PubMed ID: 17108316
[TBL] [Abstract][Full Text] [Related]
71. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
Covic M; Covic M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
[TBL] [Abstract][Full Text] [Related]
72. Diversity of calcium action in regulation of mammalian calmodulin-dependent cyclic nucleotide phosphodiesterase.
Sharma RK
Indian J Biochem Biophys; 2003 Apr; 40(2):77-91. PubMed ID: 22900295
[TBL] [Abstract][Full Text] [Related]
73. Activity of cyclic AMP phosphodiesterases and adenylyl cyclase in peripheral nerve after crush and permanent transection injuries.
Walikonis RS; Poduslo JF
J Biol Chem; 1998 Apr; 273(15):9070-7. PubMed ID: 9535895
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
75. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA
J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121
[TBL] [Abstract][Full Text] [Related]
76. Human Ca2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization.
Michibata H; Yanaka N; Kanoh Y; Okumura K; Omori K
Biochim Biophys Acta; 2001 Jan; 1517(2):278-87. PubMed ID: 11342109
[TBL] [Abstract][Full Text] [Related]
77. The PDE1A-PKCalpha signaling pathway is involved in the upregulation of alpha-smooth muscle actin by TGF-beta1 in adventitial fibroblasts.
Zhou HY; Chen WD; Zhu DL; Wu LY; Zhang J; Han WQ; Li JD; Yan C; Gao PJ
J Vasc Res; 2010; 47(1):9-15. PubMed ID: 19672103
[TBL] [Abstract][Full Text] [Related]
78. β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells.
Zhai K; Hubert F; Nicolas V; Ji G; Fischmeister R; Leblais V
PLoS One; 2012; 7(10):e47826. PubMed ID: 23094097
[TBL] [Abstract][Full Text] [Related]
79. Multiprotein Complex With TRPC (Transient Receptor Potential-Canonical) Channel, PDE1C (Phosphodiesterase 1C), and A2R (Adenosine A2 Receptor) Plays a Critical Role in Regulating Cardiomyocyte cAMP and Survival.
Zhang Y; Knight W; Chen S; Mohan A; Yan C
Circulation; 2018 Oct; 138(18):1988-2002. PubMed ID: 29871977
[TBL] [Abstract][Full Text] [Related]
80. Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants.
Fidock M; Miller M; Lanfear J
Cell Signal; 2002 Jan; 14(1):53-60. PubMed ID: 11747989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
